{"nct_id":"NCT06042478","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-07","start_date":"2023-11-15","start_date_type":"ACTUAL","primary_completion_date":"2025-08-18","primary_completion_date_type":"ESTIMATED","completion_date":"2027-07-20","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["NVS"]}